Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. by Tso, Jonathan L et al.
UCLA
UCLA Previously Published Works
Title
Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase 
expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Permalink
https://escholarship.org/uc/item/5gz2p89z
Journal
Molecular cancer, 14(1)
ISSN
1476-4598
Authors
Tso, Jonathan L
Yang, Shuai
Menjivar, Jimmy C
et al.
Publication Date
2015-11-06
DOI
10.1186/s12943-015-0459-1
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH Open Access
Bone morphogenetic protein 7 sensitizes
O6-methylguanine methyltransferase
expressing-glioblastoma stem cells to
clinically relevant dose of temozolomide
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Abstract
Background: Temozolomide (TMZ) is an oral DNA-alkylating agent used for treating patients with glioblastoma.
However, therapeutic benefits of TMZ can be compromised by the expression of O6-methylguanine methyltransferase
(MGMT) in tumor tissue. Here we used MGMT-expressing glioblastoma stem cells (GSC) lines as a model for
investigating the molecular mechanism underlying TMZ resistance, while aiming to explore a new treatment strategy
designed to possibly overcome resistance to the clinically relevant dose of TMZ (35 μM).
Methods: MGMT-expressing GSC cultures are resistant to TMZ, and IC50 (half maximal inhibitory concentration) is
estimated at around 500 μM. Clonogenic GSC surviving 500 μM TMZ (GSC-500 μM TMZ), were isolated. Molecular
signatures were identified via comparative analysis of expression microarray against parental GSC (GSC-parental).
The recombinant protein of top downregulated signature was used as a single agent or in combination with TMZ,
for evaluating therapeutic effects of treatment of GSC.
Results: The molecular signatures characterized an activation of protective stress responses in GSC-500 μM TMZ,
mainly including biotransformation/detoxification of xenobiotics, blocked endoplasmic reticulum stress-mediated
apoptosis, epithelial-to-mesenchymal transition (EMT), and inhibited growth/differentiation. Bone morphogenetic
protein 7 (BMP7) was identified as the top down-regulated gene in GSC-500 μM TMZ. Although augmenting BMP7
signaling in GSC by exogenous BMP7 treatment did not effectively stop GSC growth, it markedly sensitized both
GSC-500 μM TMZ and GSC-parental to 35 μM TMZ treatment, leading to loss of self-renewal and migration capacity.
BMP7 treatment induced senescence of GSC cultures and suppressed mRNA expression of CD133, MGMT, and
ATP-binding cassette drug efflux transporters (ABCB1, ABCG2), as well as reconfigured transcriptional profiles in GSC by
downregulating genes associated with EMT/migration/invasion, stemness, inflammation/immune response, and cell
proliferation/tumorigenesis. BMP7 treatment significantly prolonged survival time of animals intracranially inoculated
with GSC when compared to those untreated or treated with TMZ alone (p = 0.0017), whereas combination of two
agents further extended animal survival compared to BMP7 alone (p = 0.0489).
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Conclusions: These data support the view that reduced endogenous BMP7 expression/signaling in GSC may contribute
to maintained stemness, EMT, and chemoresistant phenotype, suggesting that BMP7 treatment may provide a novel
strategy in combination with TMZ for an effective treatment of glioblastoma exhibiting unmethylated MGMT.
Keywords: BMP7, Glioblastoma, Temozolomide, MGMT, Glioblastoma stem cells
Background
Glioblastoma is the most common and lethal primary
malignant brain tumor which remains a challenging dis-
ease to treat. The current standard-of-care for patients
with newly diagnosed glioblastoma consists of maximal
surgical resection, radiotherapy (RT), and concomitant
and adjuvant chemotherapy with temozolomide (TMZ).
Despite aggressive treatment, all patients eventually suffer
from tumor progression because their tumors become re-
sistant to maintenance TMZ, and the median survival
among all patients is only 12–15 months from diagnosis.
Although TMZ is the principal first-line chemotherapeutic
agent used for the treatment of glioblastoma, it does not
significantly prolong the overall survival of patients without
methylation of the MGMT promoter [1–3]. The anti-
tumor activity of TMZ depends on its ability to methylate
DNA at the O-6 positions of guanine residues, which will
produce methylguanine adducts, triggering a continuous
cycle of DNA base mismatch repair, which leads to
double-strand breaks and base mispairing, ultimately indu-
cing cell apoptosis [4, 5]. MGMT is a cellular DNA repair
protein that neutralizes the cytotoxic effects of TMZ by
directly transferring methyl groups from the O-6-position
of guanine to a cysteine residue [6]. Therefore, glioblast-
oma tumors expressing MGMT have been implicated as a
major intrinsic mechanism of resistance to TMZ, although
a different mechanism independent of MGMT has been
reported [7]. Methylation of MGMT promoter has become
an important prognostic and predictive factor for TMZ
treatment of newly diagnosed GBM, and high MGMT pro-
tein expression in patient tumors is associated with TMZ
resistance in patients [8, 9]. Thus, treatment strategies to
overcome MGMT-dependent or independent chemoresis-
tance are urgently needed.
It has been hypothesized that glioblastoma stem cells
(GSC) are responsible for post-treatment tumor recur-
rence because they are drug-resistant cells that can sur-
vive treatment and regenerate tumors [10–13]. A recent
study using a genetically engineered mouse model of gli-
oma has provided direct evidence and demonstrated that
a quiescent subset of endogenous stem-like glioma cells
is located at the apex of a cellular hierarchy in tumor
maintenance, and is responsible for tumor recurrence
after TMZ therapy fails [14]. This study thus supports
the view that TMZ can only deplete the proliferative dif-
ferentiated tumor population, but not the quiescent
GSC. It is generally accepted that GSC are a small subset
of slow-cycling stem-like glioblastoma tumor cells within
a tumor tissue, that are capable of clonally self-renewing
and growing as tumor spheres and migrating radially
outward in culture, and reconstituting a tumor in mouse
brain that recapitulates the histopathological features of
the patient tumor from which the GSC were derived
[15–17]. A previous study indicated that MGMT-negative
CSC line can be depleted with 50 μM TMZ treatment in
culture whereas GSC line expressing MGMT transcripts
results in a 10-fold increase of TMZ-resistance (500 μM)
[18]. Similarly, we also found that GSC clones resistant to
radiochemotherapy expressed upregulated MGMT when
compared to that of autologous sensitive GSC clones [13].
Current adjuvant TMZ treatment is given as 150–
200 mg/m2 on days 1 to 5 of a 28-day cycle, which results
in concentrations of between 15–35 μM in glioma tumor
tissue [19]. Therefore, identifying a new strategy to
sensitize the MGMT-expressing GSC to clinically achiev-
able dose of TMZ in brain will have important implica-
tions for the management of glioblastoma patients with
unmethylated MGMT promoter.
In this study, we extended our previous work and used
MGMT-expressing GSC that survived 500 μM TMZ
treatment (GSC-500 μM TMZ) to explore the potential
intrinsic factors that may be linked to triggering TMZ
resistance. By comparing gene-expression profiles be-
tween GSC-500 μM TMZ and parental GSC (GSC-par-
ental), we explored a series of genes that characterized
intracellular stress responses and self-defense mecha-
nisms against high-dose TMZ in GSC-500 μM TMZ.
Moreover, BMP7 was identified as a top down-regulated
gene in GSC-500 μM TMZ. We thus evaluated the treat-
ment efficacy of recombinant BMP7 on GSC and tested
the synergistic effect of BMP7 and low-dose TMZ on
the treatment of MGMT-expressing GSC both in vitro
and in vivo. We further investigated the potential
MGMT-independent mechanisms contributing to the
BMP7-mediated sensitization of MGMT-expressing GSC
to TMZ.
Results
GSC cultures contain tumorigenic clones that are resistant
to high-dose TMZ and express upregulated MGMT
Three previously established and characterized patient
tumor-derived MGMT unmethylated GSC cell lines,
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D431, S496 and E445 [13, 17, 20] were used to study
TMZ sensitivity. A cell viability assay was performed to
determine the dose-dependent effect and IC50 of TMZ
for GSCs (Fig. 1a). Cells were plated at clonal density
and treated with various doses of TMZ (0, 200, 500, 800,
1000 μM) and incubated for 48 h prior to measurement
of their growth activity. All three GSC lines are relatively
resistant to 200 μM TMZ, but showed a dose response
to higher-dose TMZ treatment (Fig. 1a); the IC50 value
of TMZ against three tested GSC lines is found to be ap-
proximately 500 μM. To understand how high-dose
TMZ affects the growth activity of GSC, we compared
their cell-cycle distributions in their normal untreated
state, and after both 48-hour and 7-day exposure to
TMZ. The cell cycle analysis at 48-hr time point of
500 μM TMZ treatment revealed a robust cell cycle ar-
rest in the S phase for all 3 tested GSC (D431/23 %,
S496/31 %, E445/27 % Vs. 52 %, 62 %, 53 % respectively),
whereas arrest in G2/M phase was only observed in 2
cultures (12 %, 14 %, 20 % Vs. 40 %, 13 %, 32 % respect-
ively) (Fig. 1b, a–f ). TMZ-induced cellular damage was
clearly seen on day-7 cultures and resulted in a sub-G1
peak where 26–42 % of apoptotic cells were determined
(Fig. 1b, g–i). Meanwhile, several clonogenic cells sur-
vived and started to re-populate tumor spheres, and
large tumor spheres can be seen on day 10 for all three
Fig. 1 A selection of clonogenic GSC clones able to survive high-dose TMZ treatment from MGMT-expressing GSC culture lines. a. Growth activity of
GSC lines treated with indicated TMZ doses was determined via MTS-based cell proliferation assay. The dose response curve of GSCs derived from each
patient tumor, is presented both individually and combined together. The concentration of TMZ required for 50 % inhibition of GSC viability in vitro
(IC50) was estimated using the mean of growth activity of 3 GSC lines. Values of TMZ-treated cells represent the percentage of growth relative to that
of untreated cells, which was converted to 100 %. Data represent mean values ± SD of triplicate measurements of three independent experiments.
*p < 0.05 and **p < 0.001 in relation to untreated control. b. Cell cycle distribution of GSC treated with and without 500 μM TMZ was determined on
day 2 or day 7 after treatment. Numbers in the respective cell cycle distributions indicate the percentage of cells in each phase of the cell cycle. c. In
vitro selection of clonogenic survival of GSC in the presence of 200 or 500 μM TMZ or left untreated. Photos were taken at indicated time periods after
treatment. d. sqRT-PCR analysis of MGMT mRNA expression levels in untreated parental GSC (GSC-parental) and clonogenic clones surviving 500 μM
TMZ treatment (GSC-500 μM TMZ). The graph shows the mean values of fold change for MGMT mRNA expression levels in indicated GSC-500 μM
TMZ lines relative to those of untreated GSC-parental. All values are relative to those of the internal control gene β-actin, with values of GSC-500 μM
TMZ representing the fold change relative to that of GSC-parental, which was converted to 1. Data represent mean values ± SD of triplicate
measurements in three independent experiments. *p < 0.05 and **p < 0.001 in relation to GSC-parental
Tso et al. Molecular Cancer  (2015) 14:189 Page 3 of 17
cultures (Fig. 1c). When compared to untreated, parental
GSC, these clonogenic GSC surviving 500 μM TMZ,
designated as GSC-500 μM TMZ, expressed upregulated
DNA repair enzyme MGMT mRNA as determined by
semi-quantitative RT-PCR (sqRT-PCR) (Fig. 1d). To test
whether GSC-500 μM TMZ possess tumorigenic capacity,
cells were stereotactically injected into the brains of severe
combined immunodeficient (SCID) mice. Mice which re-
ceived cells derived from GSC-parental (5 mice per GSC
line) or GSC-500 μM TMZ (5 mice per GSC line) all de-
veloped tumors, while delayed tumor development was
determined in all 3 GSC-500 μM TMZ lines (Fig. 2a, b).
The H-E staining of xenograft tumors initiated by GSC-
parental or GSC-500 μM TMZ showed no histological dif-
ference between the two groups, indicating that in vitro
selection by high-dose TMZ did not alter/destroy the
properties and histological origin of GSC. All tumors
demonstrated invasive growth of gliomas with diffuse in-
filtration into the surrounding tissue and vessels, and reca-
pitulated the typical histopathological features of human
glioblastoma (Fig. 2c). These data indicated that MGMT-
expressing GSC-parental cultures contain minor stem-like
tumor-initiating cells with inherent properties that allow
them to adapt to deadly stress induced by high-dose TMZ.
Fig. 2 Clonogenic clones surviving 500 μM TMZ treatment showed a delay in tumor formation compared to those of unselected parental GSC.
a. Kaplan-Meier survival curves of indicated GSC-parental (5 mice/group) and GSC-500 μM TMZ (5 mice/group). P-values were calculated using
the Log-rank test. The survival curves were plotted for individual (a–c) and combined 3 GSC (d). b. Representative macrophotographic image of
glioma xenografts initiated by GSC-parental and GSC-500 μM TMZ that are growing in the intracranial site. c. Representative hematoxylin and
eosin (HE) staining of xenograft tumors. Brain tissues from mice injected with either GSC-parental (D431, S496, E445) or GSC-500 μM TMZ
(D431, S496, E445) display invasive growth of gliomas and exhibit histopathological features of human glioblastoma, including hypercellularity
(a, h), hyperchromatism (b, i), pleomorphism and mitosis (c–e, j–l), vascular endothelial hyperplasia (f, m), oligodendroglial components (g, n), and
chondrocytic components (o)
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Molecular profiles of GSC-500 μM TMZ revealed an
intrinsic defense strategy against high- dose TMZ
To explore the intrinsic mechanisms allowing clono-
genic clones to overcome or adapt to 500 μM TMZ, we
performed a comparative high-density expression micro-
array analysis of GSC-parental (n = 3 patients, duplicate/
6 samples) and GSC-500 μM TMZ survived one and
two-cycle 500 μM TMZ treatment (n = 3 patients, 6
samples). Probe set signals on the expression array that
were ≥ 1.5-fold higher or lower in GSC-500 μM TMZ
group versus the GSC-parental group with a pairwise t-
test (P < 0.05) were selected, and 36 informative genes
were obtained (Table 1). As anticipated, the overall gene
expression profile revealed the activation of stress re-
sponse pathways for self-defense and stabilizing cellular/
genomic integrity, including blocking of endoplasmic
reticulum stress-mediated apoptosis (GRP), biotransform-
ation of xenobiotics/detoxification (NNMT), inhibition of
insulin/Akt signaling (EGR1, INPP4B), induction of
cellular quiescence/growth inhibition (CDKN1A, NR2F1,
SLFN5. PPP1R14C, ZNF652, PRRG4), stabilization of
mitochondria/microtubule network (MAP4), promoting
EMT, migration/invasion (RUNDC3B, MCAM, NR2F1,
RRAS, FN1, MALAT1), angiogenesis (GRP, APOLD1,
FN1, MALAT1), and suppression of cell proliferation and
differentiation (downregulated BMP7, FJX1). The distinct
gene expression in GSC-parental and GSC-500 μM TMZ
was confirmed by sqRT-PCR analysis (Additional file 1:
Figure S1). To test whether upregulated “defense signa-
tures” indeed provide protection from TMZ treatment,
cells were treated with siRNA targeting selected defense
signatures for 48 h prior to receiving 35 μM TMZ. Active
clonogenic growth was detected in cells treated with
siRNA negative control with or without addition of 35 μM
TMZ even though less growth was seen in TMZ-treated
wells, the on-target knockdown of selected defense signa-
tures have resulted in a severe loss of ability to repopulate
tumor spheres (Fig. 3a, a; Additional file 1: Figure S2).
Moreover, adding 35 μM TMZ after knockdown of
defense genes further lysed tumor sphere-initiating cells
(Fig. 3a, a; Additional file 1: Figure S2), which was not
seen in those transfected with siRNA targeting housekeep-
ing gene, glyceraldehyde-3-Phosphate Dehydrogenase
(GAPDH) (Fig. 3a, a). On-target gene knockdown by
siRNA treatment was verified by sqRT-PCR analysis
(Fig. 3a, b) and gene knockdown at protein levels was
validated in two representative genes, using Western blot
analysis (NNMT) and enzyme assay (GAPDH) (Fig. 3b).
The differential growth effect of siRNA treatment on GSC
was further validated by cell proliferation assay and a
TMZ-specific synergy was demonstrated in GSC knock-
down of defense signature, not GAPDH (p < 0.001)
(Fig. 3c). These results suggest that some of the upregu-
lated genes in GSC-500 μM TMZ not only serve as
essential factors for maintaining GSC integrity, but also
play a key role in maintaining resistance against lethal
stress induced by high-dose TMZ.
BMP7 treatment reverses chemoresistance of
MGMT-expressing GSC to TMZ
BMP7 was identified as the top down-regulated gene in
GSC-500 μM TMZ by expression microarray analysis
when compared to autologous GSC-parental and sug-
gested the endogenous BMP7 expression in GSC may
play a role in regulating drug resistance to TMZ. We
therefore, focused our study on BMP7 for the following
reasons: recombinant BMP7 is readily available, it can
cross the blood-brain barrier (BBB) [21], and it has been
regarded as a metastatic suppressor gene. Since all tested
GSC cultures expressed BMP type 2 receptors (BMPR2)
(Fig. 4a, a), and BMP7 treatment induced phosphoryl-
ation of Smad1/5/8 protein (Fig. 4a, b), we hypothesized
that augmenting BMP7 signaling in GSC would attenu-
ate stemness and EMT properties, and sensitize cells to
TMZ treatment via switching off defense genes. To test
this hypothesis, both GSC-parental and GSC-500 μM
TMZ were seeded and either treated with TMZ (35 μM),
BMP7 (100 ng/ml), combination of BMP7 and TMZ, or
left untreated. In the combination treatment, GSC were
pre-treated with BMP7 for overnight, and again on the
following day by adding BMP7 to cultures for 30 min
prior to TMZ treatment. All treatments were repeated
for 5 consecutive days. GSC treated with 35 μM TMZ
only showed minimal growth effect when compared to
untreated GSC. Although GSC treated with BMP7
showed less cell migration and proliferation when com-
pared to untreated GSC, no cell death/lysis was observed
in cultures, and cells continued to grow after treatment
(Fig. 4b). In contrast, combination treatment with BMP7
and TMZ showed a progressive suppression of both cell
proliferation and migration starting on day 5 after the
first treatment, eventually leading to cell apoptosis/lysis
(Fig. 4b, c, a, b). The treatment effects were further evalu-
ated by a β-galactosidase senescence assay, and the data
showed that senescence cells were detected only in cul-
tures treated with BMP7 alone or combination with TMZ
(Fig. 4c, c). These observations suggest that protective fac-
tors that cause chemoresistance which include anti-
senescence, were attenuated when BMP7 signaling was ac-
tivated, rendering cells more vulnerable, and thereby more
sensitive to low-dose TMZ.
BMP7 modulates molecular properties of GSC associated
with treatment resistance
Previous studies have pointed out that the expression of
MGMT/unmethylated MGMT [2, 3, 18], CD133 [22–24],
and ATP-binding cassette drug efflux transporters
[25–27] are important intrinsic factors contributing to
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Table 1 Molecular signatures and defense profiles of glioblastoma stem cells (GSC) resistant to 500μM TMZa
Gene Fold change P value Functional involvement
MB2: metastasis related protein 9.48 0.037251 human lung cancer cell metastasis-related gene
GRP: gastrin-releasing peptide 3.03 0.012739 activates stress responses; blocks ER stress-mediated
apoptosis; angiogenesis
NNMT: nicotinamide N-methyltransferase 3.02 0.016864 biotransformation of xenobiotics, detoxification,
drug resistance, DNA repair
RUNDC3B: RUN domain containing 3B 2.63 0.022848 tumor invasion, tumorigenic capacity, malignant transformation
PPP1R14C: protein phosphatase 1, regulatory (inhibitor)
subunit 14C
2.45 0.038521 tumor suppressor, upregulates early growth response 1 and
PTEN gene expression
FAM46A: family with sequence similarity 46, member A 2.35 0.026347 retinal signaling pathways
SYTL2: synaptotagmin-like 2 2.07 0.006201 vesicle trafficking
EGR1: early growth response 1 2.00 0.012287 impaired insulin/Akt signaling, reduced glucose uptake,
autophagy, Sirt1 expression
ZNF652: zinc finger protein 652 1.88 0.024023 a transcriptional repressor, tumor suppressor
MAP4: microtubule-associated protein 4 1.85 0.007016 stabilizes mitochondria, microtubule network, and
cell viability
APOLD1: apolipoprotein L domain containing 1 1.85 0.006038 angiogenesis, blood-brain permeability
ANKRD10: ankyrin repeat domain 10 1.85 0.011112 unknown
C5orf32: chromosome 5 open reading frame 32 1.79 0.005850 stress tolerance
SLFN5: Schlafen family member 5 1.74 0.025479 growth-inhibitory responses, tumor suppressor
MCAM: melanoma cell adhesion molecule 1.73 0.004659 cell adhesion, EMT
MST150: MSTP150 1.72 0.010533 induced by nerve growth factor
NR2F1: Nuclear receptor subfamily 2, group F, member 1 1.68 0.003457 tumor dormancy, cell motility, and invasiveness
PRRG4: Proline rich Gla (G-carboxyglutamic acid) 4
(transmembrane)
1.65 0.009662 downregulates ERK 1/2 signaling, cell cycle control
RRAS: related RAS viral (r-ras) oncogene homolog 1.62 0.022906 maintains endothelial barrier function, cell migration
CDKN1A: cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.60 0.018892 cell cycle regulator, cellular quiescence, tumor suppressor
FAM114A1: family with sequence similarity 114, member A1 1.59 0.026679 neuronal cell development
INPP4B: inositol polyphosphate-4-phosphatase, type II, 105kDa 1.57 0.004296 phospholipid metabolism, tumor suppressor,
inhibits PI3K/Akt signaling
FN1: fibronectin 1 1.56 0.037537 EMT, cell adhesion and migration, angiogenesis
C6orf57: chromosome 6 open reading frame 57 1.54 0.036557 mitochondrial function
VDAC1: voltage-dependent anion channel 1 1.52 0.005105 respiratory electron transport
PSAT1: phosphoserine aminotransferase 1 1.52 0.029482 serine synthesis pathway; amino acid/phospholipid/nucleotide
synthesis
ZEB1: zinc finger E-box binding homeobox 1 1.51 0.038506 transcriptional repression of interleukin 2
MALAT1: metastasis associated lung adenocarcinoma
transcript 1
1.51 0.021777 EMT, migration, invasion, metastasis, angiogenesis
FAT3: FAT tumor suppressor homolog 3 (Drosophila) 1.51 0.014515 controls neuronal morphology
MFSD2: major facilitator superfamily domain containing 2 −1.53 0.006302 plays a role during fasting and adaptive thermogenesis
NUP160: nucleoporin 160kDa NUP98: nucleoporin 98kDa −1.55 0.049580 promotes mitotic spindle assembly, contributes to proper
kinetochore functions
NUP98: nucleoporin 98kDa −1.59 0.032310 a nuclear pore complex component; a transcription factor
DPP6: dipeptidyl-peptidase 6 −1.06 0.013619 interaction with extracellular matrix
FJX1: four jointed box 1 (Drosophila) −1.62 0.004725 growth and differentiation
NRP2: neuropilin 2 −1.63 0.041599 cardiovascular development, axon guidance, and tumorigenesis
BMP7: bone morphogenetic protein 7 (osteogenic protein 1) −1.98 0.002699 cartilage and bone formation; differentiation and proliferation
ER endoplasmic reticulum; EMT epithelial-to-mesenchymal transition
aProbe set signals on the expression array that were ≥ 1.5-fold different in GSC-500 μM TMZ (n=3 patients, 6 samples) when compared to GSC-parental (n = 3
patients, duplicate samples) by a pairwise t-test (P < 0.05), were selected. Samples were permutated 100 times by dChip, and 36 annotated genes with median
FDR = 4 % were obtained
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TMZ resistance. We therefore, tested whether we can
establish this relationship using MGMT-expressing
GSC model. Although BMP7 did not suppress GSC
growth effectively in culture as compared to combin-
ation treatment (Fig. 4b, c), the BMP7 treatment has
induced the loss of CD133 transcripts accompanied
by down-regulated MGMT and two drug efflux trans-
porters, ABCB1 (also known as P-glycoprotein or multi-
drug resistance protein 1) [25, 26] and ABCG2 (breast
cancer resistance protein, BCRP) [26, 27] in GSC (Fig. 5a).
The expression of SRY (sex determining region Y)-box 2
(SOX2), a marker for neural stem cells, was also decreased
but in a lesser degree. Down-regulation of stem cell-
associated markers in GSC was more likely to decrease
their expression in formerly expressing cells in response
to BMP7 treatment, rather than depleting them due to all
mRNA samples being extracted 24 h after the first treat-
ment was performed (day 3). Unexpectedly, the expression
of glial fibrillary acidic protein (GFAP), a marker of differ-
entiated astrocytes, was not upregulated, but is almost un-
detectable, while the expression of Nestin remained
unchanged. GFAP expressing neural stem cells (NSC)
have been reported, although CD133-expressing cells rep-
resent a more quiescent NSC-like population [28, 29]. A
comparable transcriptional pattern was also seen in GSC
treated with BMP7 + TMZ: the expressions of ABCB1 and
Fig. 3 Inhibition of GSC self-renewing capacity by knockdown of selected defense signatures of GSC-500 μM TMZ. a. GSC-500 μM TMZ were
treated with siRNA targeting indicated defense signatures of GSC-500 μM TMZ in the presence or absence of 35 μM TMZ. Representative photos
(D431-500 μM TMZ) were taken 7 days after treatment (a). On-target gene knockdown by siRNA treatment was verified by sqRT-PCR analysis 48 h
after transfection (b). The graph shows the mean values of mRNA expression levels of siRNA-targeted genes in GSC-500 μM TMZ lines relative to
those of treated with negative control siRNA. All values were relative to those of the internal control gene β-actin, with values of GSC-500 μM
TMZ representing the percentage of mRNA expression levels relative to that after treatment with negative control siRNA, which was converted to
100 %. Data represent mean values ± SD of triplicate measurements in three independent experiments in two GSC lines (D431-500 μM TMZ,
E445-500 μM TMZ). All gene-targeted values represent statistically significant reduction of mRNA levels (P < 0.001). b. Gene knockdown verification
on the protein level. The siRNA-mediated knockdown of GAPDH and NNMT expressions in GSC at protein levels was determined by measurement
of GAPDH enzymatic activity (a) and Western blot analysis (b), respectively. Data represent mean values ± SD of triplicate measurements in three
independent experiments. **p < 0.001 in relation to treatment with negative control siRNA. c. The effects of gene knockdown on GSC self-
renewing capacity. The GSC growth under the indicated treatment conditions was determined by MTS assay, which was carried out 72 h after
transfection. Data represent mean values ± SD of triplicate measurements in three independent experiments. *p < 0.05 and **p < 0.001 in relation
to cells treated with negative control siRNA
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Fig. 4 Sensitization of MGMT-expressing GSC to low-dose TMZ treatment by recombinant BMP7. a. The mRNA expression of bone morphogenetic
protein receptor, type II (serine/threonine kinase) (BMPRII) in GSC was verified by sqRT-PCR analysis (a) and BMP7-induced Smad1/5/8 phosphorylation
in GSC was assayed by Western blot analysis (b). b. GSC-parental and GSC-500 μM TMZ were treated with 35 μM TMZ, BMP7 (100 ng/ml) or
combination of BMP and TMZ. Treatment procedures were described in the text. Representative photos were taken 6–8 days after treatment.
c. The growth effects (a), cell apoptosis (b), and cell senescence (c) induced by the indicated treatments on GSC were determined by a cell
proliferation assay, the measurement of Caspase3/7 activity, and senescence-associated beta-galactosidase staining respectively. Blue staining in
cells is indicative of cellular senescence (c). Data in (a) and (b) represent mean values ± SD of triplicate measurements in three independent
experiments. *p < 0.05 and **p < 0.001 in relation to untreated GSC
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ABCG2 were almost not detectable. In contrast, the ex-
pression of these tested markers remained present in GSC
treated with TMZ alone, but the expression levels were
lower than those of untreated GSC (Fig. 5a). Moreover,
down-regulation of MGMT mRNA levels by BMP7 treat-
ment was not due to the reversal of MGMT promoter
methylation status (Additional file 1: Figure S3), suggest-
ing methylation-independent pathways of MGMT
expression regulation. In order to obtain more compre-
hensive knowledge about gene regulation by BMP7 treat-
ment in GSC, we performed an expression microarray
analysis to identify genes that were differentially expressed
between untreated and BMP7-treated GSC (Fig. 5b,
Table 2) in both GSC-parental and GSC-500uM TMZ.
DNA microarray demonstrated that BMP7 treatment up-
regulated a cluster of genes associated with metastasis
Fig. 5 BMP7-induced transcriptional reconfiguration and sensitization of MGMT-expressing GSC to TMZ therapy. a Representative results of sqRT-PCR
analysis of stemness and TMZ resistance-associated genes in GSC-500 μM TMZ modulated by the indicated treatments. The graph shows the mean
values of percentage of mRNA expression levels of indicated genes in D431-500 μM TMZ treated with TMZ (35 μM), BMP7 (100 ng/ml) or their
combination relative to those of untreated D431-500 μM TMZ. All values were normalized to those of the internal control gene β-actin,
with values of treated D431-500 μM TMZ representing the % relative to that of untreated D431-500 μM TMZ, which was converted to
100 %. Data represent mean values ± SD of triplicate measurements in three independent experiments. *p < 0.05 and **p < 0.001 in relation to
GSC-parental. b Analyses of gene expression profiles of BMP7-treated D431-parental and D431-500 μM TMZ. Probe set signals on expression array that
were≥ 1.25-fold different in BMP7-treated GSC cultures when compared to untreated GSC cultures were selected (P < 0.05). All plots show normalized
gene expression values converted into a heatmap. The log2 of the fold difference is indicated by the heatmap scale at the bottom. Each column is an
individual GSC samples (P = parental, T = 500 μM TMZ selected). Each row is a single probe set measurement of transcript abundance for an individual
gene. The genes and gene functions are listed in the same order from top to bottom as the corresponding table (Table 2). c Kaplan-Meier survival
curves of untreated, TMZ, BMP7, and combination-treated animals implanted with D431-parental intracranially. The treatment schedules and dosages
were described in Methods. P-values were calculated using the Log-rank test. d Representative macrophotographic image of glioma
xenografts treated with indicated therapy. e H-E staining of xenograft tumors from d
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Table 2 Transcriptional modulation in GSC by BMP7 treatmenta
Gene Fold change P value Functional involvement
I. Upregulated genes
RASAL2: RAS protein activator like 2 3.37 0.019083 tumor and metastasis suppressor
ATXN1: ataxin 1 2.59 0.013118 chromatin-binding factor that repress Notch signaling, cell
differentiation
CD44: CD44 molecule (Indian blood group) 2.59 0.023871 a receptor for hyaluronic acid; modulates Smad1 activation
in the BMP7 signaling
ZNF638: protein 638 2.33 0.030429 adipocyte differentiation
CDC14B: CDC14 cell division cycle 14 homolog B
(S. cerevisiae)
2.09 0.027588 cell cycle control
TGFBR1: Transforming growth factor, beta receptor I 1.99 0.015786 cell cycle arrest in epithelial cells; growth inhibition, cell apoptosis
PIK3C2A: Phosphoinositide-3-kinase, class 2, alpha
polypeptide
1.63 0.037372 functions in insulin signaling, premature senescence and
oxidative apoptosis
AKAP10: A kinase (PRKA) anchor protein 10 1.59 0.024294 control of cell proliferation
DLC1: deleted in liver cancer 1 1.58 0.041191 metastasis suppressor gene, EMT arrest
BRPF3: bromodomain and PHD finger containing, 3 1.44 0.035113 promotes formation of acetyltransferase complexes, stimulates
transcription
SLC20A1: Solute carrier family 20 (phosphate
transporter), member 1
1.40 0.042665 cellular metabolism, signal transduction, and nucleic acid and
lipid synthesis
RASEF: RAS and EF-hand domain containing 1.39 0.045602 tumor suppressor, induction of apoptosis, inhibition of
proliferation
MLL: myeloid/lymphoid or mixed-lineage leukemia 1.38 0.024547 regulates neural progenitor proliferation and neuronal and glial
differentiation
CDK6: cyclin-dependent kinase 6 1.37 0.047985 augments accumulation of p53, decreases tumor growth when
overexpression
IGF1R: insulin-like growth factor 1 receptor 1.34 0.045232 stimulates stem cell differentiation via AKT activation; premature
senescence
POU2F1: POU class 2 homeobox 1 1.34 0.032549 anti-inflammation/immune response, cell apoptosis, regulation
of NF-kappaB
IL6ST: interleukin 6 signal transducer (gp130, oncostatin
M receptor)
1.29 0.022673 stimulates osteoblast differentiation, maintains bone formation
ZNF395: zinc finger protein 395 1.29 0.030385 suppresses cell migration and invasion
ERN2: endoplasmic reticulum to nucleus signaling 2 1.28 0.037335 activation of the unfolded protein response
LGR5: leucine-rich repeat-containing G protein-coupled
receptor 5
1.27 0.030355 universal epithelial stem cell marker
IRAK1BP1: interleukin-1 receptor-associated kinase 1
binding protein 1
1.27 0.024291 downregulation of inflammatory cytokines, anti-inflammation,
growth inhibition
ARIH2: Ariadne homolog 2 (Drosophila) 1.26 0.032696 inhibits cell proliferation
II. Downregulated genes
NOTCH3: Notch homolog 3 (Drosophila) −1.25 0.037102 EMT, maintenance of NSC in an undifferentiated quiescent state,
angiogenesis
ASXL1: additional sex combs like 1 (Drosophila) −1.25 0.016868 suppresses adipogenesis, transcriptional repression
SEMA6A: sema, transmembrane, and cytoplasmic
domains, 6A
−1.25 0.041608 vascular development; tumor angiogenesis; neuronal
development
QPRT: quinolinate phosphoribosyltransferase −1.25 0.027582 resistance to oxidative stress; suppression of spontaneous
cell death
GPRC5B: G protein-coupled receptor, family C, group 5,
member B
−1.26 0.029052 insulin resistance; inflammatory signaling; promotes
ERK1/2 activation
TRO: trophinin −1.26 0.033855 promotes EMT, invasive and metastatic phenotype; tumor
formation
MFI2: antigen p97 identified by mAb 133.2 and 96.5 −1.26 0.034824 cell proliferation and tumorigenesis
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suppressor (RASAL2, DLC1), EMT/migration/invasion ar-
rest (DLC1, ZNF395), tumor suppressor/cell cycle control
(CDC14B, TGFBR1, AKAP10, RASEF, ARIH2), cell differ-
entiation and transcription activation (ATXN1, ZNF638,
BRPF3, MLL, IGF1R, IL6ST), insulin signaling/glucose up-
take/premature senescence (PIK3C2A, IGF1R), and anti-
inflammation/immune response (POU2F1, IRAK1BP1).
CD44, a receptor for hyaluronic acid, was determined to
be a top 3 upregulated gene; it has been reported that
CD44 modulated SMAD1 activation in the BMP7 signaling
pathway in chondrocytes [30], and inhibits inflammatory
bone loss [31]. Correspondingly, genes down-regulated by
BMP7 treatment are mostly associated with EMT/mi-
gration/invasion (NOTCH3, TRO, COL16A1), stemness/
anti-differentiation/transcriptional repression (NOTCH3,
ASXL1), DNA repair/anti-apoptosis/resistance to oxida-
tive stress (QPRT), cell proliferation/tumorigenesis (MFI2,
COL16A1), insulin resistance (GPRC5B), angiogenesis
(NOTCH3, SEMA6A), and inflammation/immune
response (GPRC5B, SCARA5, CLEC7A). The selected
genes with distinct expression levels in cells were
confirmed by sqRT-PCR analysis (data not shown).
These gene profiles therefore, support the view that
the molecular properties of EMT and stemness in
GSC may be the two key factors triggering drug
resistance. The data also suggest that BMP7 possesses
the ability of anti-EMT/migration/invasion, induction
of tumor stem cell differentiation/senescence, and
down-regulation of MGMT and drug efflux trans-
porters, thereby allowing for sensitization of GSC to
low-dose TMZ treatment.
BMP7 synergizes TMZ in treatment of GSC and extends
animal survival
To test whether anti-tumor synergy of combination
treatment in culture can be translated to in vivo treat-
ment, we performed a proof-of-principle experiment to
compare the treatment efficacy of 0.01 % DMSO (un-
treated), TMZ, BMP7, and combination of BMP7 and
TMZ, on preventing tumor initiation and progression
(enrichment of resistant clones) in animals inoculated
with GSC-parental. We chose D431-parental as the
treatment model, because the mice that were injected
with D431-parental had the shortest lifespan when com-
pared to those injected with a different line. Moreover,
D431-parental contains the highest % of CD133+ cells
(~35 %) among 3 GSC lines [20]. The administration
routes, and dosing schedules are described in Material
and Methods. Treatment with TMZ alone did not show
a survival benefit (59–63 days) when compared to the
untreated animal group (52–63 days) (p = 0.9005)
(Fig. 5c). Although BMP7 alone did not effectively stop
GSC growth in culture, treatment with BMP7 alone
demonstrated significantly extended survival of animals
(70–79 days) when compared to untreated (p = 0.0025)
or treated with TMZ alone (p = 0.0017) (Fig. 5c). The com-
bination of BMP7 with TMZ further showed a smaller, but
significant prolongation of survival (73–86 days) when
compared to treatment with BMP7 alone (p = 0.0489)
(Fig. 5c). Although all mice died of tumor development, a
more pronounced vascularity was seen in untreated and
TMZ-treated animals when compared to those treated
with BMP7 and combination therapy (Fig. 5d, e). More-
over, there was less tumor spreading seen in animals
treated with combination therapy (Fig. 5d, e). These results
suggest that BMP7 treatment not only can attenuate the
tumorigenicity of GSC and delay tumor progression, but
also can further synergize with TMZ in enhancing the sup-
pression of the tumor growth thereby providing a greater
survival benefit to animals.
Discussion
In this study, we used molecular profiles of MGMT-
expressing GSC that survived high-dose TMZ treatment,
to probe defense signatures which could be potential
treatment targets for sensitizing GSC to the clinically
relevant dose of TMZ. Using this non-biased strategy,
we have identified informative gene profiles that are
likely to contribute to resistance to high-dose TMZ
treatment. These protective stress response profiles are
similar to our previous finding in GSC clones that
survived radiochemotherapy (RT + TMZ) [13], which
expressed molecular and functional characteristics
resembling the anti-aging/anti-stress effects of caloric/
Table 2 Transcriptional modulation in GSC by BMP7 treatmenta (Continued)
METTL3: methyltransferase like 3 −1.28 0.046969 plays a role in the efficiency of mRNA splicing and processing
MTMR11: myotubularin related protein 11 −1.35 0.017165 unknown; cisplatin resistance-associated protein
COL16A1: collagen, type XVI, alpha 1 −1.37 0.020495 stimulates tumor proliferation and invasion
SCARA5: Scavenger receptor class A, member 5
(putative)
−1.40 0.024406 innate immune response; inflammatory response
CLEC7A: C-type lectin domain family 7, member A −1.40 0.009915 innate immune response; inflammatory response; migration and
proliferation
NSC neural stem cells; EMT epithelial-to-mesenchymal transition
aProbe set signals on the expression array that were ≥ 1.25-fold different in BMP7 treated GSC cultures (n = 2, GSC-parental and GSC-500 μM TMZ) when compared
to untreated GSC cultures (n = 2, GSC-parental and GSC-500 μM TMZ) were selected
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glucose restriction (GR), by which both insulin-like
growth factor 1 (IGF1) and insulin/Akt signaling were
reduced [32–34]. The transcription profiles suggested
that the stress/drug resistance of GSC-500 μM TMZ is
associated with cellular quiescence, EMT/invasiveness,
suppressed growth and differentiation, and impaired in-
sulin/Akt signaling. We unintentionally found BMP7 to
be a top down-regulated gene in GSC-500 μM TMZ,
and thus hypothesized that reduced BMP7 expression/
signaling helped them maintain their dedifferentiated
state, which prevents them from premature senescence,
and renders them more resistant to standard treatment,
since it only targets more differentiated/aging cells [35].
Indeed, treatment with BMP7 alone allows for delaying
tumor development/progression without TMZ com-
pared to untreatment or treatment with TMZ alone,
suggesting that the anti-tumor activity of BMP7 is inde-
pendent of MGMT status in GSC. This notion is further
supported by the finding that BMP7 treatment does not
reverse the unmethylation status of GSC. Our data sup-
port the view that induction of cell senescence/aging
and loss of EMT/migration/invasion properties by
BMP7 treatment are likely to contribute to the reduction
of tumorigenesis and progression, leading to prolonged
animal survival. Moreover, BMP7 treatment down-
regulates the expression of MGMT and ATP-binding
cassette drug efflux transporters in GSC may provide an
additional support mechanism to synergize low-dose
TMZ in treatment of GSC. Therefore, BMP7 treatment
induces cooperative mechanisms which allow for
sensitization of GSC to low-dose TMZ treatment, and
extends animal survival. Similar to our finding, a recent
study showed that MGMT methylation status does not
predict TMZ response in GSC model, and both methyl-
ated and unmethylated MGMT bands can be amplified
in TMZ-resistant GSC lines [36]. Another study found
that some GBM lines resistant to TMZ treatment do not
express MGMT protein, but rather exhibit a down-
regulation of DNA mismatch repair protein or reduced
methylation of LINE-1 repetitive elements (enhances
transposon activity) [37]. Therefore, we believe that
down-regulation of MGMT expression by BMP7 is not
the sole mechanism allowing for GSC responding to
low-dose TMZ treatment.
BMP7 is a member of the transforming growth factor-
β (TGF-β) superfamily of growth factors. The binding of
BMP7 to its receptors, BMP type 1 and type 2 receptors
(BMPR1/2), induces the phosphorylation of intracellular
SMAD1/5/8, which can block the nuclear translocation
of phosphorylated SMADs 2/3 induced by TGF-β, which
in turn results in suppressed TGF-β signaling. BMP7
plays a pivotal role in the osteoblast differentiation/bone
formation, kidney development, and promoting brown
adipocyte differentiation [38–40]. Recently, BMP7 has
been implicated in regulation of cancer pathogenesis and
metastasis, possibly due to its ability to counteract TGF-
β-induced, SMAD3-dependent EMT [41, 42]. Reduced
levels of BMP7 in primary breast and lung cancer tissues
are significantly associated with the formation of clinic-
ally overt bone metastases for breast cancer patients and
lymph node metastasis for lung cancer patients [43, 44].
Down-regulated BMP7 expression was also determined
in primary human prostate cancer tissue when com-
pared with normal prostate luminal epithelium [45]. The
animal studies further demonstrated that BMP7 treat-
ment significantly inhibited internal bone growth of
breast cancer cells and prostate cancer bone metastases,
suggesting that reduced BMP7 signaling in tumor cells
may enhance tumorigenesis and EMT with the develop-
ment of metastatic properties via enhanced capacity for
cell migration and invasion [43, 45]. Our previous [13]
and current data support the view that EMT linked with
dedifferentiation/stemness are possibly underlying treat-
ment resistance of GSC, which can be overridden by
augmenting BMP7 signaling. The removal of factors as-
sociated with stemness or anti-stress properties in GSC
by BMP7 treatment is evident by demonstrating the sig-
nificantly downregulation of mRNA levels of CD133,
MGMT, and efflux transporters with concomitant induc-
tion of cell senescence and susceptibility to low-dose
TMZ treatment. A previous study has shown that induc-
tion of EMT in mammary epithelial cells by exposure to
TGF-β1 or overexpression of Snail or Twist (EMT-indu-
cing transcription factors), can generate cells with stem
cell properties [46]. Another study also found that ZEB1,
an EMT activator, represses expression of stemness-
inhibiting microRNA [47]. Likewise, we previously found
that primary glioblastoma possess molecular properties
of mesenchymal stem cells (MSC) and express cellular
and molecular markers that have been implicated in
EMT/myofibroblastic phenotype [48]. In particular, we
found primary glioblastoma tumor cells express CD105
(endoglin), which is an MSC surface marker and a
component of the TGF-β receptor complex that binds to
TGF-β1 and TGF-β3, and modulates TGF-β signaling
[48], thus suggesting a direct link between TGF-β-
induced EMT and the gain of stem cell properties in
glioblastoma and GSC. TGF-β1 promotes hematopoietic
stem cell quiescence by downregulating Akt activity and
upregulating FOXO3 activity [49]. Likewise, we also
found that GSC clones sensitive to radiochemotherapy
(RT + TMZ) exhibited activated Akt activity with
increased glucose usage, whereas resistant clones
expressed upregulated CD133, SOX2 and MGMT, with
reduced Akt activity and increased AMPK-SIRT1-FOXO
Axis and favored the fatty-acid oxidation pathway for
their energy source [13]. In this study, we also found
that treatment with BMP7, an antagonist of TGF-β
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system, downregulated EMT and stemness transcription
program accompanied by upregulation of genes associ-
ated with insulin signaling/AKT and cell senescence,
suggesting that BMP7 modulates stemness and EMT
may be involved in a metabolic switch, which led to in-
creased drug sensitivity. Similarly, a recent study showed
that BMP2 can sensitize glioblastoma-stem-like cells to
TMZ (500 μM) by downregulating both hypoxia-
inducible factor-1α (HIF-1α) and MGMT [50]. The
study also demonstrated a direct binding of HIFs to the
MGMT promoter under hypoxia, and the treatment
with BMP2 can abrogate HIF-1a binding to MGMT
promoter [50]. The hypoxia/HIF-dependent promotion
of the stemness/cellular quiescence and EMT in cancer
progression has been well addressed and reviewed
[51–53]. Correspondingly, it was reported that ABC efflux
transporters contain several binding sites for EMT-
inducing transcription factors, and overexpression of
Twist, Snail, and FOXC2 can increase promoter activity of
ABC efflux transporters by binds directly to the E-box ele-
ments of ABC efflux transporters [54]. These findings
therefore support the notion that BMP7-mediated
downregulation of CD133, MGMT and efflux trans-
porters accompanied with increase sensitivity to TMZ
may be achieved via the removal of factors that
promote EMT and stemness properties in GSC.
We previously reported that GSC clones surviving ra-
diochemotherapy (RT + TMZ), or purified CD133+ GSC,
expressed upregulated angiogenesis- and EMT-associated
genes [13, 17]. In this study, we further found that BMP7
treatment markedly upregulates genes associated with cell
differentiation and senescence while downregulates genes
associated with stemness properties in GSC, including
CD133 expression, suggesting that the expression of
CD133 may be an indication of both stemness and drug
resistance in GSC [22–24]. Recent reports indicated that
CD133 is a marker of bioenergetic stress in hypoxic
human glioma [55] and that activation of hypoxia/HIF-
1alpha enhanced the self-renewal activity of CD133+ GSC
and inhibited the induction of CSC differentiation [56].
Moreover, the expression of CD133 facilitates EMT [57],
whereas CD133 silencing inhibits stemness properties and
enhances chemoradiosensitivity of tumor stem cells [58].
In this study, we identified several reported EMT inducers
as molecular signatures of GSC-500 μM TMZ, including
MCAM, FN1, and MALAT1 [59–61]. Correspondingly,
NOTCH3, which both gates neural stem cell activation
[62] and contributes to TGF-β-induced EMT [63], was
detected as a downregulated gene by BMP7 treatment.
Meanwhile, a NOTCH signaling repressor, ATXN1 [64],
was identified as an upregulated gene by BMP7 treatment.
Thus, maintaining the low activity of BMP7 signaling in
GSC may be required for sustaining EMT, stemness,
and multidrug-resistant phenotype. Our finding is in
agreement with that of others showing that BMP7 release
from endogenous neural precursor cells can induce tumor
stem cell differentiation and reduce the ability for tumor
initiation, therefore, providing a protective action in
animals [65]. Likewise, treatment with a BMP7 variant
suppressed the tumorigenicity of stem-like glioblastoma
cells and reduced angiogenesis and brain invasion [66].
The optical imaging study further provided direct evi-
dence of BMP7-induced cell cycle arrest in glioma model
[67]. Notably, it was reported that BMP7-induced
senescence of prostate cancer stem-like cells is reversible;
withdrawal of BMP7 treatment restarted growth of these
cells in bone [68]. Therefore, combination with chemo-
therapy would provide extended survival time by eliminat-
ing the cells, preventing them from regrowing back.
Genetic approaches for elucidation of mechanisms by
which BMP7 downregulates MGMT, ABC efflux trans-
porters, stemness, and EMT would further facilitate our
understanding the process and ability to identify new
treatment targets and strategies for preventing treatment
resistance and tumor recurrence.
Conclusion
The data presented in this study showed that BMP7
treatment can sensitize MGMT-expressing GSC to the
clinically relevant dose of TMZ both in vitro and in vivo.
The gene profiles pointed out that BMP7-mediated
TMZ sensitization in GSC may be associated with repro-
gramming of transcriptional profiles, particularly the
downregulation of genes which contributed to EMT/mi-
gration/invasion, stemness, and drug resistance. Our
data therefore, suggest a potential therapeutic utility of
BMP7, a neuroprotective agent in cerebral hypoxia/is-
chemia [69, 70], combined with TMZ, for treating newly
diagnosed glioblastoma or recurrent diseases exhibiting
unmethylated MGMT.
Methods
Cell cultures
Glioblastoma stem cell (GSC) cultures used in this study
were established from glioblastoma tumor tissues de-
rived from patients who underwent surgery at Ronald
Reagan UCLA Medical Center. All samples collected
were under patients’ written consent, and were approved
by the UCLA Institutional Review Board. The tumors
were enzyme-digested and washed, followed by red
blood cell (RBC) lysis of the pellet. The primary cells
were cultured in a serum-free stem cell culture medium
consisting of DMEM/Ham’s F-12 (Mediatech, Manassas,
VA), 20 ng/ml human recombinant epidermal growth
factor (EGF, Sigma-Aldrich, St. Louis, MO), 20 ng/ml
basic fibroblast growth factor (FGF, Chemicon, Billerica,
MA), 10 ng/ml leukemia inhibitory factor (LIF, Chemi-
con), and B27 without vitamin A (Invitrogen, Carlsbad,
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CA). The tumor spheres were dissociated and replated at
clonal density and continually passaged until the clono-
genic cells were stably maintained. As previously de-
scribed [13, 17], the D431 GSC culture line was classified
as mesenchymal subtype whereas S496 and E445 culture
lines were classified as proneural (PN) subtype. All three
tumorigenic GSC cultures contained CD133+ cells
(39.5 %, 9.6 % and 1.5 % respectively), exhibited wild-type
IDH1/IDH2 and unmethylated MGMT promoter and
expressed MGMT transcripts (10, 14, Additional file 1:
Figure S3).
Isolation of clonogenic GSC resistant to high-dose TMZ
GSC cultures were seeded at clonal density overnight,
and treated with 500 μM TMZ the next day. Fresh
media was replaced every three days. TMZ treatment
was repeated on day 7 after the first treatment to ensure
that clonogenic survivors are truly resistant to 500 μM
TMZ. Clonogenic cells that have survived were isolated,
expanded, and designated as GSC-500TMZ-C1 (treatment
cycle 1). Established GSC-500TMZ-C1 cultures were then
reseeded and re-treated with 500 μM TMZ twice (day 1
and day 7), and the stable clonogenic cells continued to
grow were harvested and designated as GSC-500TMZ-C2.
In order to maintain resistant clones in the long-term cul-
tures, cells were re-exposed to 500 μM TMZ treatment
after thawing or prior to using in experiments.
Cell proliferation
The effects of TMZ or siRNA treatment on GSC growth
were determined by a 3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS/PMS) colorimetric assay according to the manufac-
turer’s instructions (Promega).
Cells were seeded in 96-well tissue culture plates at a
density of 6,000–10,000 cells per well per 100 μL stem
cell media in triplicate in the presence or absence of
indicated treatment. Cells were incubated for 48–72 h,
and absorbance was measured at 490 nm after a 4-hour
incubation with MTS/PMS reagents.
Cell apoptosis
Cell apoptosis in BMP7- and TMZ-treated GSC was de-
termined by Apo-ONE® Homogeneous Caspase-3/7 Assay
kit (Promega), according to the manufacturer's protocol.
One hundred microliters Homogeneous Caspase-3/7 Re-
agent was added to each well followed by 2 min mixing
on a plate shaker. Plates were incubated at room
temperature for 2 h. Fluorescence intensity was measured
with a fluorescence microplate reader (Synergy HT,
BioTek) at the excitation and emission wavelengths of
485 nm and 528 nm respectively. Multiple readings
were taken at one-hr intervals. Data are expressed as
the relative fluorescence units (RFU).
Cell-cycle distribution
2–5 × 105 dissociated cells were washed twice with cold
PBS. Cell pellets were resuspended in 1 ml propidium iod-
ide hypotonic DNA staining buffer (50 mg/ml propidium
iodide, 0.1 % Triton X-100, and 0.1 % sodium citrate in
PBS) and mix well. Samples were kept in 4 °C away from
light for a maximum of 1 h before acquisition on the flow
cytometer for cell cycle analysis (FACScan, Becton
Dickinson), which used DNA content as a measure of pro-
gression in cell cycle and as means of detecting apoptotic
cells. Apoptotic cells with degraded DNA were detected
as a hypodiploid or "sub-G1" peak in a DNA histogram.
Microarray procedures, data analysis and gene
annotation
Molecular profiling and analysis were performed as de-
scribed [17]. Briefly, cDNA was generated and converted
to cRNA probes using standard Affymetrix protocols and
hybridized to Affymetrix GeneChip U133 Plus 2.0 Array.
The chips were scanned using the GeneArray scanner
(Affymetrix). The CEL files generated by the Affymetrix
Microarray Suite version 5.0 were converted into DCP
files using the DNA-Chip Analyzer (dChip/2008; http://
www.hsph.harvard.edu/cli/complab/dchip/). The DCP files
were globally normalized, and gene expression values were
generated using the dChip implementation of perfect-
match minus mismatch model-based expression index. All
group comparisons were performed in dChip. Functional
annotation of individual genes was obtained from NCBI/
Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/entrez), the
published literature in PubMed Central (NCBI/PubMed),
GeneCards (http://www.genecards.org/), and Protein
knowledge base (UniProtKB) (http://beta.uniprot.org/). All
microarray CEL files analyzed in this study are accessible
from the Gene Expression Omnibus (GEO) (Series Acces-
sion number: GSE68071).
Semi-quantitative reverse transcriptase polymerase chain
reaction (sqRT-PCR) analysis
Cells were subjected to total RNA extraction using
RNeasy kit (Qiagen, Valencia, CA). Two micrograms of
total RNA from each sample were reverse transcribed to
cDNA using a TaqMan RT Reagent Kit (Applied Biosys-
tems). Thirty cycles of PCR amplification was performed
on an Eppendorf gradient thermocycler, using 5 μL cDNA,
SYBR Green PCR Core Reagents (Applied Biosystems)
and gene-specific primers (Invitrogen). The signal inten-
sity of each specific gene was quantified using Image Lab™
Software (Gel Doc™ EZ System, Bio-Rad). The band inten-
sity of each sample was normalized to the corresponding
β-actin band intensity in order to obtain the relative
level of gene expression. The primer sequences and
expected sizes of amplified PCR products are described in
Additional file 1: Table S1.
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Western blot analysis
30 μg protein from each sample were separated on
4–20 % gradient SDS-PAGE (Bio-Rad) and transferred
onto a PVDF membrane. The blots were incubated
with phospho-Smad1 (Ser463/465)/ Smad5 (Ser463/465)/
Smad9 (Smad8) (Ser465/467) antibody (Cell Signaling) for
overnight at 4 °C. Anti-β-actin (Cell Signaling) was used
as internal control. The blots were washed and incubated
with horseradish peroxidase-conjugated anti-rabbit IgG
for 1 h. After washing, blots were incubated with Pierce
Supersignal ECL substrate, and exposed to X-ray films.
siRNA transfection
A reverse transfection protocol was done to deliver non-
silencing negative control siRNA (scrambled siRNA)
(Ambion), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) or gene-specific siRNA (Ambion), into GSCs
as previously described [13]. The transfection efficiency
and cellular toxicity due to transfection were monitored
using KDalert™ GAPDH Assay Kit (Invitrogen). Briefly, a
transfection complex was prepared by diluting siRNA in
10 μl OPTI-MEMI (Invitrogen) then mixing with 10 μL
OPTI-MEMI containing 0.3 uL Lipofectamine RNAi-
MAX transfection reagent (Invitrogen). The siRNA
transfectant was then added into each well in a 96-well
plate followed by seeding 6000–9000 cells in 100 μL
media to give a final siRNA concentration of 30 nM in
each well. Targeted gene silencing was determined 72 h
after transfection by sqRT-PCR, using a Power SYBRH
Green Cells-to-CTTM Kit (Ambion).
Methylation-specific PCR (MSP) analysis
Genomic DNA was subjected to bisulfite treatment using
the EZ DNA Methylation-Gold™ Kit (Zymo Research) fol-
lowing the manufacturer's instructions. The promoter
MGMT-MSP was performed using a two-step nested ap-
proach to amplify both methylated and unmethylated
MGMT separately as described previously [71]. Total hu-
man genomic DNA methylated by bacterial DNA methyl-
transferase and whole genome amplified DNA were used
as positive and negative controls for methylated alleles of
MGMT, respectively. The PCR products were resolved on
4 % low melting point agarose gels.
Intracranial tumor formation, BMP7 treatment, and
histopathologic analysis
To test the tumorigenic capacity of GSC, 105 viable cells
in a volume of 3 μl culture media were engrafted intra-
cranially into anesthetized NOD (CB17-Prkdcscid/J)
mice (5 weeks old; 15–16 g). Mice were then maintained
until neurological signs were observed, at which point
they were sacrificed. The brains were removed, fixed in
4 % formalin, paraffin-embedded, and sectioned. Histo-
pathologic analyses were done on paraffin slides stained
with hematoxylin-eosin (H-E) staining per standard
technique. To test whether BMP7 can sensitize TMZ for
treatment of GSC in vivo, mice were randomly divided
into four groups (5 mice per group) and each group was
received the following treatments: group 1, 0.01 %
DMSO; group 2, TMZ; group3, BMP7; group 4, BMP7 +
TMZ. GSC cells (105/3 μl/animal) were intracranially
injected followed by local delivery of vehicle (0.01 %
DMSO in 100 μl H2O) or TMZ (100 μl of 35 μM TMZ)
for group 1 and group 2 mice or BMP7 (10 ng in 100 μl
water) for group 3 and group 4 mice using an osmotic
minipump (Alzet, USA, model 1007D). The sterile pump
was implanted subcutaneously (s.c.) onto the back of an-
imals, and the drug solutions were delivered through the
cannula, which was placed through a small skull burr
hole onto the pial surface where tumor cells were im-
planted. On day 7 after local treatment, the mice of
group 2 were continuously treated with TMZ (66 mg/kg)
via oral gavage daily for 5 days, the mice of group 3
received intraperitoneal injection of BMP7 (2 μg/day) for
5 days and mice group 4 received both BMP7 (morning)
and TMZ (afternoon) for 5 days. Animals were maintained
until neurological signs were observed. Immediately after
sacrifice, the brains were removed and subjected to histo-
pathological analysis. All animal experiments in this study
were under a protocol approved by the UCLA Institutional
Animal Research Committee.
Statistical analysis
Each experiment was set up in triplicate and repeated at
least twice. Data were expressed as means ± SD and ana-
lyzed using 1-way ANOVA tests, depending on homo-
geneity of variances. Cumulative survival probabilities
were calculated using the Kaplan-Meier method. The
log-rank test was used to compare survival across
groups. All p-values were 2-sided, and those lower than
0.05 were considered significant. SPSS v19.0 for Windows
software was used for all statistical analysis.
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